Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics Corp reports a favorable outlook driven by a significant increase in its operating margin, which improved by 390 basis points year-over-year, reaching approximately 24% for FY25. The company's gross margin also showed positive momentum, increasing by 240 basis points year-over-year, indicating effective cost management and pricing strategies. Furthermore, growth in plasma revenue, fueled by premium pricing related to technology upgrades and strong performance in the transfusion management sector, underscores Haemonetics’s potential for continued expansion in high-demand market segments.

Haemonetics Corp has experienced declining sales in its Blood Center and Plasma segments, with Blood Center sales decreasing by 2.8% to $68.5 million and Plasma sales dropping 9.1% to $138.6 million, both showing performance below market expectations. The company has revised its guidance downward, now anticipating lower organic growth rates for both the Hospital segment (12-14%, down from 14-17%) and the Blood Center segment (-5% to -7%, reduced from -3% to -6%). Additionally, Haemonetics has reported an overall organic revenue growth slowdown to -0.3% in F3Q25, indicating potential challenges ahead in maintaining profitability and operating margins.